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The mycotoxin deoxynivalenol (DON) commonly contaminates cereal grains. It is ubiquitous in the Western
European diet, although chronic, low-dose effects in humans are not well described, but immunotoxicity has
been reported. In this study, two-dimensional gel electrophoresis was used to identify phosphoproteomic
changes in human B (RPMI1788) and T (Jurkat E6.1) lymphocyte cell lines after exposure to modest
concentrations of DON (up to 500 ng/mL) for 24 h. Proteins identified as having altered phosphorylation state
post-treatment (C-1-tetrahydrofolate synthase, eukaryotic elongation factor 2, nucleoside diphosphate
kinase A, heat shock cognate 71 kDa protein, eukaryotic translation initiation factor 3 subunit I and growth
factor receptor-bound protein 2) are involved in regulation of metabolic pathways, protein biosynthesis and
signaling transduction. All exhibited a greater than 1.4-fold change, reproducible in three separate
experiments consisting of 36 gels in total. Flow cytometry validated the observations for eukaryotic
elongation factor 2 and growth factor receptor-bound protein 2. These findings provide further insights as to
how low dose exposure to DON may affect human immune function and may have potential as mechanism-
based phosphoprotein biomarkers for DON exposure.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Fusaria mycotoxins such as deoxynivalenol (DON), contaminate a
wide range of cereal crops [1]. Epidemiological studies have
implicated mycotoxins in some mass food poisoning outbreaks and
DON has been one of the compounds found in highest concentrations
[2,3].
Animal studies have shown that DON may induce generalized GI
tract toxicity, emetic effects and feed refusal [4–6]. Studies in animal
models and immortalized cell lines have also shown that DON
exposure modulates immune function by specifically influencing
proinflammatory responses and white blood cell distribution and
proliferation in several organs [7–10].
The primary mode of action of DON is thought to be its ability to
bind to eukaryotic ribosomes and thereby inhibit protein synthesis
[8,11]. Secondary mechanisms such as disruption of cell signaling,
differentiation, growth and macromolecular synthesis have also been
associated with DON exposure [8,11].
Although biomarkers promise to provide more objective measures
of DON exposure, to date few studies have been conducted to identify
biomarkers of exposure or effect. Recent reports highlight the value of
urinary DON as a biomarker of recent exposure [12–14] while
immunoglobulins and pro-inflammatory cytokines have been pro-
posed as potential biomarkers of effect in relation to the immuno-
modulatory effects of the compound [8,15].
The development and application of “omics” techniques to develop
potential mechanism-based biomarkers is a promising approach and
we recently identified a number of proteins altered in expression
following DON exposure in human cells lines [16]. We now extend
this work to compare phosphoprotein expression in human B
(RPMI1788) and T (Jurkat E6.1) lymphocyte cell lines exposed to
DON at a maximum concentration of 500 ng DON/mL for a period of
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up to 54 h. These cell types represent major cellular components of
the adaptive immune response and have been used extensively
previously [17,18]. A panel of phosphoproteins which exhibited
validated altered phosphorylation state across these cell lines is
described. This is the first study looking at post-translational
modifications due to DON exposure using a proteomics approach.
The phosphoproteins identifiedmay represent valuable biomarkers to
further understand how chronic exposure to DON affects human
immune function.
2. Materials and methods
2.1. Reagents
RPMI 1640 (+ L-glutamine) medium was from Gibco (Invitrogen
Ltd., Paisley, UK); DON, 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenylte-
trazolium bromide (MTT), gelatine from cold water fish skin, protease
inhibitor cocktail and phosphatase inhibitor cocktail were supplied by
Sigma-Aldrich (Dorset, UK); ProteoExtract Protein Precipitation Kit
was from Calbiochem (Merck Chemicals Ltd., Nottingham, UK);
ampholytes and 24 cm pH 3–10 non-linear IPG strips were from
Bio-Rad (Hertfordshire, UK); SYPRO Ruby and Pro-Q Diamond
phosphoprotein stain was from Invitrogen (Paisley, UK); acetonitrile,
formic acid and trifluoroacetic acid used for MS analysis or sample
preparation were of HPLC quality (Fisher Scientific, Leicestershire,
UK); HPLC-grade water was prepared with a Neptune Ultimate
System (Purite Ltd., Oxon, UK); sequencing grade trypsin for protein
digestion was from Promega (Southampton, UK); goat anti-rabbit
IgG-PE was from Santa Cruz Biotechnology (Heidelberg, Germany);
eukaryotic elongation factor 2 (eEF2) (phospho T56+T58) rabbit
monoclonal antibody was from Abcam (ref. Ab82981,UK); growth
factor receptor-bound protein 2 (GRB2) rabbit polyclonal antibody
against amino acid residues surrounding Y209 was from Abnova (ref.
PAB4939, UK).
2.2. Cell culture and DON treatment
The culture and treatment with DON of the human B lymphocyte
cell line (RPMI1788, ECACC, UK) and human T lymphocyte cell line
(Jurkat E6.1, ECACC, UK) was performed with cells being grown at
37 °C in a humidified atmosphere consisting of 5% CO2 air, in RPMI
1640 (+ L-glutamine) medium supplemented with 20% (v/v) heat-
inactivated FCS or 10% (v/v) heat-inactivated FCS, respectively. Cells
were kept in the exponential growth phase, at a concentration of
3×105 cells/mL. Stock solutions and subsequent working solutions of
DONwereprepared in absolute ethanol.Working solutionsofDONwere
prepared with a maximum concentration of 0.05% absolute ethanol.
Vehicle control cells were prepared in the samemanner as DON treated
samples including the addition of the vehicle control (0.05% ethanol),
instead of DON. Cell treatments were conducted in flat bottom 96-well
and 12-well plates (Fisher Scientific, Leicestershire, UK). Cells were
treatedwithDON for aperiodof up to54 h,with concentrations of 250 ng
and 500 ng DON/mL for Jurkat E6.1 and RPMI1788 cells, respectively. At
the end of the incubation period, cells were either stored at−80 °C or
immediately used for cell viability measurements, proteomic studies
andflow cytometry experiments. Cell viabilitywas assessedusing the3-
(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT)
assay. Cells were grown in flat bottom 96-well plates at a concentration
of 6×105 cells/mL per well with DON for a period of up to 54 h, in a
humidified atmosphere consisting of 5% CO2 air, at 37 °C. At the end of
the each treatment period, 10 μL of MTT were added to the cells and
plates were incubated for 4 h. Subsequently, 100 μL of 10% (w/v) SDS in
0.01 M HCl were added and the plate incubated overnight. On the
following day, absorbance levels were recorded at 540 nm and 690 nm
using an iEMS Reader MF (Labsystems, Cambridge, UK). Each plate
contained a positive control consisting of cells incubated with 9% (v/v)
Triton X-100 prior to the addition of MTT. Doses of 250 ng DON/mL and
500 ng DON/mLwere selectedon thebasis ofpreviously conductedMTT
experiments for Jurkat E6.1 and RPMI1788 cell lines respectively [16].
2.3. Cell lysis and two-dimensional gel electrophoresis
Cells were grown in T75 tissue culture flasks and 8×106 cells were
lysed with 200 μL of lysis buffer (7 M urea, 2 M thiourea, 4% (w/v)
CHAPS, 64 mM DTT and 1% (v/v) protease and phosphatase inhibitor
cocktails) per condition. The lysates were centrifuged at 13,250×g for
15 min and the supernatant treated with ProteoExtract Protein
Precipitation Kit (Calbiochem, Merck Chemicals Ltd., Nottingham, UK)
according to the manufacturer's protocol. After resuspending the
protein pellets in lysis buffer, the lysate was centrifuged at 13,250×g
for 15 min and the supernatant collected. The protein concentration of
the supernatants was determined using the Bradford assay (Bio-Rad,
Hertfordshire, UK). An aliquot (350 μg) of each supernatantwas applied
to a 24 cm pH 3–10 non-linear IPG strip overnight, allowing for the
passive rehydration of the IEF strips. IEF was carried out using the
ProteanIEF system (Bio-Rad, Hertfordshire, UK) with the following
program: (1) 250 V, 8 h; (2) 10000 V, 2.5 h; (3) 60000 Vh, at a limit of
10000 V; (4) 500 V until equilibration. The first equilibration step was
carried out by washing the strips for 15 min in a buffer containing 2%
(w/v) DTT, 6 M urea, 0.05 M Tris–HCl (pH 8.8), 2% (w/v) SDS, and 20%
(v/v) glycerol. The second equilibration step (15 min) used the same
buffer but with 2.5% (w/v) iodoacetamide replacing DTT. For the second
dimension, strips were transferred onto SDS-PAGE gels containing 10%
(w/v) premixed acrylamide, prepared with a multicasting chamber
(Bio-Rad, Hertfordshire, UK). Migration was carried out for 6 h at a
constant voltage of 200 V in a Protean Plus DoDecaCell tank (Bio-Rad,
Hertfordshire, UK), at 10 °C. Gelswere incubated in 50% (v/v)methanol,
7% (v/v) acetic acid overnight, were washed three times in ultra-pure
water for 5 min and subsequently stained with Pro-Q Diamond
phosphoprotein stain for 2 h. Gels were then destained three times in
a 20% (v/v) acetonitrile, 50 mM(w/v) sodiumacetate pH4.0 solution for
30 min and subsequently washed twice in ultra-pure water for 5 min.
After imaging and for spot excision purposes, gels were incubated
overnight in SYPRO Ruby stain. On the following day, gels were washed
for 30 min in 10% (v/v)methanol, 7% (v/v) acetic acid and subsequently
washed twice in ultra-pure water for 5 min and imaged. Three
independent experiments comprising triplicate samples for each
condition (n=6) were performed.
2.4. Image analysis
Gels were scanned using an FX Pro Plus imager (Bio-Rad, Hertford-
shire, UK) and the images analyzed using PDQuest software version 7.3.1
(Bio-Rad, Hertfordshire, UK) as indicated in Fig. 2. For each cell line, three
independent experiments consisting of triplicate gels for each condition
were analyzed; in total 36 gels. Only significant changes of at least 1.4-
fold (pb0.01) seen in each gel on each occasion were treated as
meaningful. The quantitation and statistical analysis of changes to spot
intensity is achieved by (i) generation of an optical density reading for
each spot detected; (ii) automatic determination of spot density; (iii)
generation of Gaussian modeling for precise identification and quanti-
tation of spots; (iv) automatic determination of standard deviation and
coefficient of variation and (v) conduction of statistical analysis based on
the number of replicate groups and the number of gels per group. Each
set of 6 gels was analyzed twice using the software.
2.5. Identification of proteins using peptide mass fingerprinting
2.5.1. Sample preparation
Spots selected by the previous steps were excised and transferred
into a 96-well plate using the ProteomeWorks SpotCutter robot (Bio-
Rad, Hertfordshire, UK). The excised pieces of gel were processed
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automatically by aMassPREPworkstation (Waters, Hertfordshire, UK)
performing the following steps: washing/destaining (1:1 mixture of
50% (v/v) acetonitrile and 50 mM ammonium bicarbonate), reduction
(DTT 10 mM, ammonium bicarbonate 100 mM), alkylation (iodoace-
tamide 55 mM, ammonium bicarbonate 100 mM), acetonitrile dehy-
dration, digestion (trypsin 6 ng/μL), extraction from the gel (1% (v/v)
formic acid, 2% (v/v) acetonitrile) and finally spotting of the peptides
and matrix (α-cyano-4-hydroxycinnamic acid, 2 mg/mL in 50% (v/v)
acetonitrile, 0.1% (v/v) trifluoroacetic acid) on the MALDI plate
(Waters Ltd., Manchester, UK).
2.5.2. MALDI-TOF MS analysis
A M@LDI L/R MALDI-TOF mass spectrometer (Waters Ltd.,
Manchester, UK), operating in positive ion reflectron mode, was
used to obtain the peptide mass spectra. Spectra were processed and
calibrated externally with a tryptic digest of alcohol dehydrogenase.
Internal calibration was performed using a single trypsin autodiges-
tion peak (m/z 2211.105) as a Lockmass point. Monoisotopic peak
masses presentingm/z ratios from 900 to 2800 were submitted to the
Mascot search engine (Matrix Science Ltd., London, UK; http://www.
matrixscience.com) in order to identify proteins.
2.5.3. Database search for protein identification
Searches were generally performed using the Swiss-Prot database,
up to one missed cleavage site, mass error of 200 ppm and variable
modifications of carbamidomethyl (C) and oxidation (M). Further
details of parameters used and any variations are detailed in
Supporting Information. Protein identifications were accepted on
the following criteria: five or more matching peptides; a MOWSE
score of more than 56; sequence coverage greater than 20%. Details of
peptide mass lists used for searches and proteins identified are
supplied in Appendix A.
2.6. Identification of proteins using MALDI-TOF tandemmass spectrometry
2.6.1. Sample preparation
Spots selected by the previous steps were excised and washed
twice with ultra-purewater, modified digestion buffer (1:1 mixture of
100 mM ammonium bicarbonate and 50% (v/v) acetonitrile), 100%
acetonitrile and 100 mM ammonium bicarbonate. Subsequently,
excised pieces of gel were washed with 100% (v/v) acetonitrile,
dried for 20 min at 37 °C and incubated with 10 μL of sequencing
grade trypsin (12.5 ng/μL) in digestion buffer, on ice for 15 min. The
supernatant was removed and replaced with 50 mM ammonium
bicarbonate. The trypsin digestion was carried out for 12–16 h at
37 °C. The supernatant of the digestion was then transferred into a
new tube and the excised pieces of gel were extracted with 50% (v/v)
acetonitrile, 0.1% (v/v) trifluoroacetic acid, and 100% (v/v) acetonitrile
washes. Subsequently, excised pieces of gel were sonicated and the
supernatant was pooled with the supernatant of the digestion.
Extracted peptides were vacuum-centrifuged (Vacufuge, Eppendorf
France SARL, Le Pecq, France) and resuspended in 10 μL 0.1% (v/v)
trifluoroacetic acid. Extracted peptides were desalted with C18
reverse-phase Zip-Tip (Millipore, Molsheim, France) according to
the manufacturer's instructions. Peptides were eluted with 2.5 μL of
50% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid, and mixed at a
1:1 ratio with MALDI matrix (10 mg/mL α-cyano-4-hydroxy-cin-
namic acid (CHCA) matrix in 70% (v/v) acetonitrile, 0.1% (v/v)
trifluoroacetic acid) for spotting.
2.6.2. MALDI-TOF MS/MS analysis
MS and MS/MS analyses of tryptic peptides were performed using
the 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems/MDS Sciex,
California, USA). After screening all MALDI sample positions in MS-
positive reflector mode using 2000 laser shots between m/z 750 and
4000, the fragmentation of automatically selected precursors was
performed at a collision energy of 1 kV using air as collision gas
(pressure, ~2×10−6 Torr). Up to 15 of the most intense ion signals
per spot position having an S/N greater than 80 were selected as
precursors for MS/MS acquisition.
2.6.3. Database search for protein identification
Protein identification was performed by peptide mass fingerprint-
ing and/or specific MS/MS peptide sequencing. The combined MS and
MS/MS spectra from were processed using ProteinPilot 3.0 software
program (Applied Biosystems, California, USA) with Mascot (Matrix
Science Ltd., London, UK; http://www.matrixscience.com) as the
database search engine (V 2.0). Searches were performed against the
IPI human database, version 3.66. TheMascot searches were run using
the following parameters: methionine oxidation (M) as variable,
cysteine carbamidomethylation (C) as fixed; one missed cleavage
allowed; precursor tolerance at 50 ppm, MS/MS fragment tolerance
set to 0.2 Da, and charge set to +1. Identification was assigned to a
protein spot feature if the protein score was calculated to be greater
than 60, correlating to a confidence interval greater than 95%
(Table 1).
2.7. Flow cytometry confirmation of eEF2 and GRB2
Cells were fixed in 1% (v/v) paraformaldehyde and subsequently
resuspended in PBS. Cell concentration was adjusted to 2×106 cells/
mL and an aliquot of 500 μL was permeabilized in 2× permeabilization
buffer (PBS, 2.5 mM EDTA, 4% (v/v) fish skin gelatin and 1% (v/v)
Triton X-100). Permeabilized cells were incubated with rabbit anti-
human eEF2 (phosphor T56+T58) (Abcam, UK) and GRB2 (Y209)
(Abnova, Taiwan) as primary antibody and subsequently incubated
with a goat anti-rabbit IgG-PE-conjugated secondary antibody. Flow
cytometry quantitative analysis was conducted using a FACSCalibur
(Becton Dickinson, UK). Analysis of data was performed using the
CellQuest™ Software (Becton Dickinson, UK). Results are presented in
Arbitrary Units (AU) resulting from the ratio between the mean
fluorescence intensity (MFI) of unstained samples (negative control
samples) and stained samples (vehicle control and treated samples).
Each experiment contained a negative control consisting of untreated
Jurkat E6.1 or RPMI1788 cells. While vehicle control and treated
samples were incubated with respective antibodies, negative control
samples were not stained with any antibodies. At the end of the
experimental procedure, negative control samples were analyzed in
the same manner as vehicle control and treated samples. Reproduc-
ibility was assured by conducting three independent experiments
with each sample repeated at least three times.
2.8. Statistical analysis
Cell viability results are presented as means±SD. Overall
experimental reproducibility was assured by conducting five inde-
pendent experiments consisting of triplicate repeats of vehicle control
samples and treated samples. Overall experimental reproducibility of
2–DE gel results was assured by conducting three independent
experiments comprising triplicate repeats of vehicle control gels and
treated gels. In total, 18 gels were run for each cell line. Statistical
differences were evaluated with a Student's t-test, pb0.01 using the
statistical package included in PDQuest software version 7.3.1 (Bio-
Rad, Hertfordshire, UK). Flow cytometry experiments are presented as
mean of AU±SD. Overall experimental reproducibility was assured
by conducting three independent experiments consisting of three
repeats of vehicle control samples and treated samples. For cell
viability and flow cytometry experimental approaches, differences
were evaluated with a Student's t-test, pb0.01 (SPSS 15.0, USA).
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3. Results
3.1. Measurement of cell viability
As can be seen in Fig. 1, the two cell lines differ in their sensitivity
to DON with a higher dose required in RPMI1788 cells to induce a
similar reduction in cell viability. In both cell lines reduced cell
viability is generally seen after 24 h incubation. When compared to
vehicle-control cells, the concentrations of 250 and 500 ng DON/ml
gave a statistically significant reduction in the cell viability in Jurkat
E6.1 and RPMI1788, respectively (pb0.01). For proteomics studies,
each cell line was treated for 24 h at its respective concentration.
3.2. Two-dimensional gel electrophoresis and protein identification
Using 2D-gel electrophoresis as described in the Methods, an
average of over 1000 spots was detected per gel and analyzed using
PDQuest software. Four spots showed reproducible phosphorylation
changes in Jurkat E6.1 cells and two spots in RPMI1788 cells (Fig. 2,
Appendix B); all spots showed at least a 1.4 fold (Appendix B).
Findings were reproducible across all gels within each experiment
and in three separate experimental treatments (pb0.01).
All spots from Jurkat E6.1 and RPMI1788 cells were successfully
identified using both MALDI-TOF MS and MALDI-TOF MS/MS
(Appendix A). In Jurkat E6.1 cells, C1-THF synthase, eEF2 and NDKA
all exhibited up-regulation in DON treated samples, while Hsc70
exhibited down-regulation in DON treated samples. In RPMI 1788
cells, eIF3i was found to be up-regulated by DON treatment, while
GRB2 was found to be down-regulated by DON treatment. No
significant changes to quantitative expression of these proteins
were identified. The proteins identified are involved in metabolism
regulation, protein biosynthesis, co-chaperoning and signaling trans-
duction (Table 2).
3.3. Flow cytometry confirmation of eEF2 and GRB2
Antibodies were only available for two of the above proteins, eEF2
and GRB2, and thus permitted the use of flow cytometry to confirm
changes in protein phosphorylation state. Comparison between
control and treated samples showed an up-regulation of 1.3-fold in
eEF2 in Jurkat E6.1 cells and a 2.5-fold down-regulation in GRB2 in
RPMI1788 cells (Fig. 3, Appendix B). All experiments contained a
negative control to account for auto-fluorescence. The results are
statistically significant (pb0.01) and confirm the pattern of expres-
sion which was obtained using 2-DE.
4. Discussion
Current studies investigating biomarkers for DON exposure have
recently resulted in the identification of DON and its glucuronide in
urine as a useful biomarker of exposure in population-based studies
[13,14,19]. We have previously identified nine potential mechanism-
based biomarkers for DON exposure, however, no phosphoprotein
Table 1
Proteins exhibiting change in phosphorylation state in Jurkat E6.1 lymphocyte cell line (spots 1–4) and RPMI1788 lymphocyte cell line (spots 5–6), identified by MALDI-TOF MS and
MALDI-TOF MS/MS. Statistical significance was considered at p≤0.01 (t-test).
MALDI-TOF MS MALDI-TOF MS/MS
Spot Protein Identified Identified
in
Accession
number
(UniProtKB)
MOWSE
score
Peptides
matched
Sequence
coverage
(%)
MOWSE
score
Peptides
matched
Sequence
coverage
(%)
Mw
(kDa)
pI Phosphorylation
State
Fold
change
1 Nucleoside diphosphate
kinase A
Jurkat
E6.1
P15531 82 7 53% 147 9 42% 17.3 5.83 Up 1.9
2 C-1-tetrahydrofolate synthase,
cytoplasmic
Jurkat
E6.1
P11586 164 25 31% 51 17 15% 102 6.89 Up 2.5
3 Heat shock cognate 71 kDa
protein
Jurkat
E6.1
P11142 126 14 26% 155 14 27% 71.1 5.37 Down 5.9
4 Eukaryotic elongation factor 2 Jurkat
E6.1
P13639 160 31 36% 317 22 28% 96.2 6.41 Up 1.9
5 Eukaryotic translation initiation
factor 3 subunit I
RPMI
1788
Q13347 151 14 58% 332 11 37% 36.9 5.38 Up 1.4
6 Growth factor receptor-bound
protein 2
RPMI
1788
P62993 84 10 41% 91 3 10% 25.3 5.89 Down 4.7
Fig. 1. Cell viability of DON in (A) Jurkat E6.1 cells at 250 ng/mL and (B) RPMI1788 cells
at 500 ng/mL measured by the MTT assay. Each bar represents the mean±SD of fifteen
replicates. SD values below 3%.
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biomarkers have been identified to date utilizing a proteomics
approach. Here we identify candidate mechanism-based phosphopro-
teins associated with low dose exposure to DON using Jurkat E6.1 and
RPMI1788 cells asmodels. The use of immortalized cell lines has several
advantages such as the cells being easy to grow and maintain, provide
unlimited experimental material, among others. Although it has been
documented that Jurkat E6.1 cells have specific abnormalities [18], they
have been widely and successfully used in signaling transduction
investigation [20] to reveal real, normal events which were further
validated in othermodels [18,21]. RPMI1788 cells have alsobeenused in
several signaling transduction studies [22], although due to their
primary origin these cells do not raise the same objections as Jurkat
E6.1 cells. Nevertheless, validation of results in immortalized cells
should be sought with primary cells prior to application in population-
based studies. Therefore while recognizing the need for caution in
interpretation of results from immortalized cells, we consider that,
based on the use of both cell lines in previously relevant work, the
results presented are both valid and valuable.
We had previously determined that a concentration of 250 ng and
500 ng DON/mL for Jurkat E6.1 and RPMI1788 cells respectively
induced changes to the proteome while limiting the levels of reduced
cell viability due to DON exposure. Reduced cell viability due to DON
exposure in the current series of experiments was similar to previous
data and thus we selected doses and an exposure period (24 h)
associated with modest (~20%) reduction in cell viability in the two
cell lines representing doses at the lower end of a range used by others
[23,24]. The above mentioned exposure period was also chosen based
on previous studies analyzing the effects of DON on immune cell lines
[16], on reproducibility and reduced variability of cell viability and a
significant decrease in cell viability after a 30 h exposure period. As
our objectivewas to induce low tomoderate changes to cell viability, a
24 h exposure period was shown to be a reasonable compromise
between establishing a real effect consistent with human exposure
and the induction of cell death.
Four proteins from Jurkat E6.1 cells and two proteins from
RPMI1788 cells displayed altered phosphorylation states reproducibly
across gel sets (Fig. 2) and their functional roles are discussed below.
4.1. Nucleotide metabolism
The phosphorylation of nucleoside diphosphate kinase A (NDKA;
E.C. 2.7.4.6) was up-regulated in Jurkat E6.1 cells after DON exposure.
This protein has been shown to be involved in DNA regulation, signal
transduction and the synthesis of nucleoside triphosphates in both
purine and pyrimidine pathways [25,26]. Studies on the phosphor-
ylation of NDKA have identified this protein as a potential biomarker
for several types of cancer [27–29]. In Jurkat E6.1 and peripheral blood
mononuclear cells, NDKA phosphorylation has been associated with T
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Fig. 2. Image of representative 2-DE gels of (A) Jurkat E6.1 control cells, (B) Jurkat E6.1 treated cells at 250 ng DON/mL, (C) RPMI1788 control cells and (D) RPMI1788 treated cells at
500 ng DON/mL. All gels were stained with Pro-Q Diamond phosphoprotein gel stain. Molecular range from 250 kDa–10 kDa, pI range from 3–10. Highlighted are six spots showing
change in phosphorylation state following DON exposure.
Table 2
Groupings of proteins based on putative function.
Putative function Proteins identified
Nucleotide metabolism Nucleoside diphosphate kinase A
Folate-mediated one-carbon
metabolism
C-1-tetrahydrofolate Synthase
Co-chaperoning Heat shock cognate 71 kDa protein
Protein biosynthesis Eukaryotic translation initiation factor 3 subunit I
Eukaryotic elongation factor 2
Signaling transduction Growth factor receptor-bound protein 2
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cell receptor signaling, protein–protein interaction [30], cell survival
and subsequent activation of cytokine production [31].
Thus, the phosphorylation of NDKA may interfere with GTP
production, thereby affecting the likes of DNA and RNA synthesis,
glycine and riboflavinmetabolism and folate biosynthesis, all of which
depend on GTP levels. However, to date, no studies have associated
the phosphorylation of NDKA with DON exposure. This observation
reinforces our findings which suggest that an up-regulation in
quantitative expression of Inosine-5′-monophosphate dehydrogenase
2 (IMDH2) and GMP synthase (GMPS) in Jurkat E6.1 cells exposed to
DON may influence purine metabolism. Nevertheless, the association
of this metabolic pathway with immune cell function after DON
exposure still remains poorly understood.
4.2. Folate-mediated one carbon metabolism
The phosphorylation state of C-1-tetrahydrofolate synthase (C1-THF
synthase) was found to be up-regulated in Jurkat E6.1 cells. C1-THF
synthase is involved in DNA synthesis as it provides 10-formyl-THF and
5,10-Methylene-THF for the de novo synthesis of nucleotides and is
considered a structural component in a multi-enzymatic purine
synthesizing complex [32]. Studies have associated C1-THF synthase
as critical to foetal development and intrauterine growth restriction.
Recently, proteomic approaches have identified this protein as a
potential marker for different types of cancer [33,34].
This effect of DON is intriguing given the observations on the up-
regulation of NDKA phosphorylation as well as the reported changes
in quantitative expression of IMDH2 and GMPS in Jurkat E6.1 cells
exposed to DON. Therefore, it would be highly informative to
investigate more deeply the relation between C1-THF synthase
phosphorylation, DON exposure and nucleotide metabolism.
4.3. Co-chaperoning
The phosphorylation of heat shock cognate 71 kDa protein (Hsc70)
was down-regulated in Jurkat E6.1 cells after DON exposure. Hsc70 is
known to have several cellular functions such as regulating the import
of proteins into the nucleus, functioning as an ATPase in the
disassembly of vesicles during trafficking and facilitating correct
protein folding by binding to nascent polypeptides [35,36]. Studies
conducted in lymphocytes isolated from human peripheral blood
mononuclear cells reported that Hsc70 expression regulates the
development of B lymphocytes and is a potential target of tyrosine
kinase activity in T lymphocytes. It has been associated with increases
in inflammation and susceptibility to autoimmunity as well as
regulating the myocardial immune response [37–40].
4.4. Protein biosynthesis
The phosphorylation of eukaryotic translation initiation factor 3
subunit I (eIF3i) and eEF2were found to be up-regulated in RPMI1788
and Jurkat E6.1 cells, respectively. These proteins are directly involved
in protein biosynthesis. The initiation phase of translation involves the
activation of several proteins such as eIF3. This protein and its
different subunits have several functions such as binding to the 40S
subunit of the ribosome and recruiting mRNA [41–43]. Although eIF3
plays important roles at multiple stages in the initiation of translation,
the molecular basis for many of its activities are poorly understood.
eIF3i has been suggested as a candidate tumour marker in
hepatocellular carcinoma and in human amniotic epithelial cells
after exposure to the carcinogen anti-benzo[a]pyrene-7,8-dihydro-
diol-9,10-epoxide [44,45]. The up-regulation of eIF3i here presented
reinforces a study on ribotoxic stress response induced by DON, where
it was reported that Protein Kinase R (PKR) was rapidly activated and
this was characterized by phosphorylation of an eukaryotic initiation
factor, eIF2α [46]. It is also known that eIF3i is phosphorylated by the
TGF-β type II receptor, allowing this protein to recruit signaling
components to receptor tyrosine kinases, and studies have shown that
DON exposure induces changes in mRNA expression of TGF-β [47,48].
One would speculate that if DON exposure affects the TGF-β type II
receptor, the latter may phosphorylate eIF3i and lead to the
impairment of signal transduction and protein synthesis. Recently,
changes to quantitative expression of eukaryotic translation factor 3
subunit 1 were identified in EL-4 cells exposed to DON, further
supporting the findings presented here [49].
eEF2 is a member of the GTP-binding translation elongation factor
family. It can be phosphorylated at threonine56 or threonine58 by eEF2
kinase leading to a decrease in eEF2 activity and therefore a decrease in
protein biosynthesis by inhibition of mRNA translation elongation [50–
52]. Studies analyzing the global phosphoproteome of colon and
hepatocellular cancer cell lines show that eEF2 phosphorylation is a
potential biomarker to assess kinase and signaling pathway activity
[53,54].
In summary, the increase in phosphorylation level of eIF3i may
lead to the impairment of the correct assembly of active ribosomes,
while the increase in phosphorylation of eEF2 may lead to a decrease
in protein biosynthesis by inhibition of mRNA translation elongation.
The findings support those of other studies looking at protein
biosynthesis in lymphoid and other tissues [55].
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Fig. 3. Quantitative confirmation of changes to phosphorylation state in (A) eEF2 and
(B) GRB2measured by flow cytometry. Each bar represents themean arbitrary units±SD
of three independent experiments each consisting of three replicates after negative control
normalization. (*pb0.01).
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4.5. Signaling transduction
GRB2 phosphorylation was down-regulated in RPMI1788 cells
after DON exposure. This protein is a regulatory subunit of signaling
molecules and pathways whose activity is modulated by tyrosine
receptor kinases, providing a link between cell surface growth factor
receptors and the Ras signaling pathway [56,57]. Tyrosine phosphor-
ylation of GRB2 interferes with the binding function of SH3 domains
to SOS proteins, thereby negatively influencing transcription factor
activation and proinflammatory responses. Studies in mouse T
lymphocytes identified GRB2 as a potential target for caspase activity
when ROS are present. Studies in mouse B lymphocytes have
associated GRB2 with B cell antigen receptor activity by sustaining
protein kinase activation and prolonged generation of second
messengers in myeloid cells [58–60].
In various models, DON has induced phosphorylation of ERK1/2
and transcription factors, such as CREB. Ultimately, these alterations
to signaling molecules and transcription factors lead to changes in
cytokine expression [61–63]. The down-regulation in GRB2 phos-
phorylation reported here reinforces the findings reported above.
4.6. Validation
To confirm the changes of protein phosphorylation detected using
2-DE, we applied a flow cytometry approach to quantify alterations in
eEF2 and GRB2 phosphorylation. The selection of these proteins for
validation was based on their biological importance and on the
limited availability of commercial antibodies for phosphoproteins.
Only two phospho-specific antibodies are currently commercially
available, therefore limiting the validation to the proteins mentioned
above. Using this approach, it was possible to confirm that both
proteins exhibited a similar DON-dependent change of phosphoryla-
tion state as seen from the 2-DE approach, as the antibodies chosen
where specific for analyzing changes to the phosphorylated state of
the proteins.
5. Conclusions
This is the first reported study on the effects of DON on the
phosphoproteome using a two-dimensional gel electrophoresis
approach. We have demonstrated that DON exposure affects
metabolic processes such as folate-mediated one carbon and
nucleotide metabolism, co-chaperoning, protein biosynthesis and
signaling transduction. T and B lymphocytes are different components
of the adaptive immune system and it was of interest that we did not
detect changes in both. Although B and T lymphocytes have similar
developmental origins and share some broad similarities in terms of
some of their signaling pathways they are two distinct cell types with
different functions. Moreover, it is possible that DON has different
targets in the two cell types thus potentially triggering different
responses leading to varying proteome changes.
The changes in phosphorylation state reported here are likely to be
meaningful taking into account the functional significance of the
proteins identified. These results could indicate, therefore, the
phosphoproteins are involved to a significant extent in purine
metabolism and protein biosynthesis. NDKA and C-1 THF synthase
may intervene directly in purine metabolism and indirectly in folate
biosynthesis, with NDKA directly involved in purine, RNA and DNA
synthesis, and C1-THF being considered a structural component of
purine metabolism due to its enzymatic activities in one carbon
metabolism. Hsc70, GRB2, eIF3i and eEF-2 all intervene directly or
indirectly in protein biosynthesis. These results reinforce previous
studies on the effects of DON exposure, indicating the productivity of
generating a search for a panel of mechanism-based biomarkers for
DON exposure.
It will be of interest to investigate to what extent these potential
DON phosphoprotein biomarkers identified in vitro may be reflected
in vivo and whether these can be applied to population-based studies
of the effects of low dose, chronic DON exposure. This will confirm the
value of using cell cultures as reliable indicators of in vivo effects.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbapap.2011.04.001.
Conflict of interest statement
The authors have declared no conflict of interest.
Acknowledgments
Protein identification by means of tandem MS was conducted at
Plate-forme de Protéomique Médicale, Institut Albert Bonniot –
Centre de Recherche, INSERM/UJF U823, Centre d'Innovation en
Biologie – CHU Grenoble, Grenoble – France coordinated by Dr. Sylvie
Michelland and Dr. Michel Sève. Work was supported by the EU
Integrated Project NewGeneris, 6th Framework Programme, Priority
5: Food Quality and Safety (Contract no. FOOD-CT-2005-016320;
NewGeneris is the acronym of the project ‘Newborns and Genotoxic
exposure risks’ http://www.newgeneris.org) and a grant from the
NIEHS, USA ES06052 to CPW.
References
[1] B.A. Rotter, D.B. Prelusky, J.J. Pestka, Toxicology of deoxynivalenol (vomitoxin),
J. Toxicol. Environ. Health 48 (1996) 1–34.
[2] F.Q. Li, Y.W. Li, X.Y. Luo, T. Yoshizawa, Fusarium toxins in wheat from an area in
Henan Province, PR China, with a previous human red mould intoxication
episode, Food Addit. Contam. 19 (2002) 163–167.
[3] C.P. Wild, A.J. Hall, Epidemiology of mycotoxin related diseases, in: H. Miller (Ed.),
The Mycota VI. Human and Animal Relationships, Springer-Verlag, Berlin, 1996,
pp. 213–225.
[4] D.M. Hughes, M.J. Gahl, C.H. Graham, S.L. Grieb, Overt signs of toxicity to dogs and
cats of dietary deoxynivalenol, J. Anim. Sci. 77 (1999) 693–700.
[5] F. Iverson, C. Armstrong, E. Nera, J. Truelove, S. Fernie, P. Scott, R. Stapley, S.
Hayward, S. Gunner, Chronic feeding study of deoxynivalenol in B6C3F1 male and
female mice, Teratog. Carcinog. Mutagen. 15 (1995) 283–306.
[6] A. Gutzwiller, L. Czegledi, P. Stoll, L. Bruckner, Effects of Fusarium toxins on
growth, humoral immune response and internal organs in weaner pigs, and the
efficacy of apple pomace as an antidote, J. Anim. Physiol. Anim. Nutr. 91 (2007)
432–438.
[7] J. van de Walle, B. Romier, Y. Larondelle, Y.-J. Schneider, Influence of
deoxynivalenol on NF-kappaB activation and IL-8 secretion in human intestinal
Caco-2 cells, Toxicol. Lett. 177 (2008) 205–214.
[8] C.J. Amuzie, J. Shinozuka, J.J. Pestka, Induction of suppressors of cytokine signaling
by the trichothecene deoxynivalenol in the mouse, Toxicol. Sci. 111 (2009)
277–287.
[9] P. Pinton, F. Accensi, E. Beauchamp, A.M. Cossalter, P. Callu, F. Grosjean, I.P.
Oswald, Ingestion of deoxynivalenol (DON) contaminated feed alters the pig
vaccinal immune responses, Toxicol. Lett. 177 (2008) 215–222.
[10] X.A. Wu, M. Kohut, J. Cunnick, T. Bailey, S. Hendrich, Deoxynivalenol suppresses
circulating and splenic leukocyte subpopulations in BALB/c mice: dose response,
time course and sex differences, Food Addit. Contam. A Chem. Anal. Control Expo.
Risk Assess. 26 (2009) 1070–1080.
[11] J.J. Pestka, A.T. Smolinski, Deoxynivalenol: toxicology and potential effects on
humans, J. Toxicol. Environ. Health B Crit. Rev. 8 (2005) 39–69.
[12] F.A. Meky, P.C. Turner, A.E. Ashcroft, J.D. Miller, Y.L. Qiao, M.J. Roth, C.P. Wild,
Development of a urinary biomarker of human exposure to deoxynivalenol, Food
Chem. Toxicol. 41 (2003) 265–273.
[13] P.C. Turner, R.P. Hopton, Y. Lecluse, K.L.M. White, J. Fisher, P. Lebailly, De-
terminants of urinary deoxynivalenol and de-epoxy deoxynivalenol in male
farmers from Normandy, France, J. Agric. Food Chem. 58 (2010) 5206–5212.
[14] P.C. Turner, J.A. Rothwell, K.L.M. White, Y. Gong, J.E. Cade, C.P. Wild, Urinary
deoxynivalenol is correlated with cereal intake in individuals from the United
Kingdom, Environ. Health Perspect. 116 (2008) 21–25.
[15] E.J. Kim, S.H. Jeong, J.H. Cho, H.O. Ku, H.M. Pyo, H.G. Kang, K.H. Choi, Plasma
haptoglobin and immunoglobulins as diagnostic indicators of deoxynivalenol
intoxication, J. Vet. Sci. 9 (2008) 257–266.
[16] A. Nogueira da Costa, R.S. Mijal, J.N. Keen, J.B.C. Findlay, C.P. Wild, Proteomic
analysis of the effects of the immunomodulatory mycotoxin deoxynivalenol,
Proteomics (2011) Mar 9. doi:10.1002/pmic.201000580.
[17] L. Severino, R. Russo, D. Luongo, R. De Luna, R. Ciarcia, M. Rossi, Immune effects of
four Fusarium-toxins (FB1, ZEA, NIV, DON) on the proliferation of Jurkat cells and
porcine lymphocytes: in vitro study, Vet. Res. Commun. 32 (Suppl 1) (2008)
S311–S313.
856 A. Nogueira da Costa et al. / Biochimica et Biophysica Acta 1814 (2011) 850–857
[18] R.R. Bartelt, N. Cruz-Orcutt, M. Collins, J.C.D. Houtman, Comparison of T cell
receptor-induced proximal signaling and downstream functions in immortalized
and primary T cells, PLoS One 4 (2009) e5430.
[19] P.C. Turner, V.J. Burley, J.A. Rothwell, K.L.M. White, J.E. Cade, C.P. Wild,
Deoxynivalenol: rationale for development and application of a urinary
biomarker, Food Addit. Contam. 25 (2008) 864–871.
[20] R.T. Abraham, A. Weiss, Jurkat T cells and development of the T-cell receptor
signalling paradigm, Nat. Rev. Immunol. 4 (2004) 301–308.
[21] W. Parson, R. Kirchebner, R. Muhlmann, K. Renner, A. Kofler, S. Schmidt, R. Kofler,
Cancer cell line identification by short tandem repeat profiling: power and
limitations, FASEB J. 19 (2005) 434–436.
[22] K.S.A. Khabar, L. al-Haj, F. al-Zoghaibi, M. Marie, M. Dhalla, S.J. Polyak, B.R.G.
Williams, Expressed gene clusters associated with cellular sensitivity and
resistance towards anti-viral and anti-proliferative actions of interferon, J. Mol.
Biol. 342 (2004) 833–846.
[23] Y. Sugita-Konishi, J.J. Pestka, Differential upregulation of TNF-alpha, IL-6, and IL-
8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a
human macrophage model, J. Toxicol. Environ. Health A 64 (2001) 619–636.
[24] R.L. Uzarski, Z. Islam, J.J. Pestka, Potentiation of trichothecene-induced leukocyte
cytotoxicity and apoptosis by TNF-alpha and Fas activation, Chem. Biol. Interact.
146 (2003) 105–119.
[25] M. Murakami, R. Kaul, P. Kumar, E.S. Robertson, Nucleoside diphosphate kinase/
Nm23 and Epstein-Barr virus, Mol. Cell. Biochem. 329 (2009) 131–139.
[26] J. Biggs, E. Hersperger, P.S. Steeg, L.A. Liotta, A. Shearn, A drosophila gene that is
homologous to a mammalain gene associated with tumor metastasis codes for a
nucleoside diphosphate kinase, Cell 63 (1990) 933–940.
[27] N. Hailat, D.R. Keim, R.F. Melhem, X.X. Zhu, C. Eckerskorn, G.M. Brodeur, C.P.
Reynolds, R.C. Seeger, F. Lottspeich, J.R. Strahler, S.M. Hanash, High levels of p19/
nm23 protein in neuroblastoma are associated with advanced stage disease and
with N-myc gene amplification, J. Clin. Invest. 88 (1991) 341–345.
[28] J. Okabe-Kado, T. Kasukabe, Y. Honma, H. Kobayashi, N. Maseki, Y. Kaneko,
Extracellular NM23 protein promotes the growth and survival of primary cultured
human acute myelogenous leukemia cells, Cancer Sci. 100 (2009) 1885–1894.
[29] B. Youn, H.D. Kim, J. Kim, Nm23-H1/nucleoside diphosphate kinase as a key
molecule in breast tumor angiogenesis, Expert Opin. Ther. Targets 12 (2008)
1419–1430.
[30] V. Mayya, D.H. Lundgren, S.I. Hwang, K. Rezaul, L.F. Wu, J.K. Eng, V. Rodionov, D.K.
Han, Quantitative phosphoproteomic analysis of T cell receptor signaling reveals
system-wide modulation of protein – protein interactions, Sci. Signal. 2 (2009)
A37–A52.
[31] J. Okabe-Kado, T. Kasukabe, Y. Honma, H. Kobayashi, N. Maseki, Y. Kaneko,
Extracellular NM23-H1 protein inhibits the survival of primary cultured normal
human peripheral bloodmononuclear cells and activates the cytokine production,
Int. J. Hematol. 90 (2009) 143–152.
[32] A.J. MacFarlane, C.A. Perry, H.H. Girnary, D. Gao, R.H. Allen, S.P. Stabler, B. Shane, P.
J. Stover, MTDHFD1 is an essential gene in mice and alters biomarkers of impaired
one-carbon metabolism, J. Biol. Chem. 284 (2009) 1533–1539.
[33] K.M. Howard, S.J. Muga, L.W. Zhang, A.E. Thigpen, D.R. Appling, Characterization of
the rat cytoplasmic C-1-tetrahydrofolate synthase gene and analysis of its
expression in liver regeneration and fetal development, Gene 319 (2003) 85–97.
[34] S. Gez, B. Crossett, R.I. Christopherson, Differentially expressed cytosolic proteins
in human leukemia and lymphoma cell lines correlate with lineages and
functions, Biochim. Biophys. Acta Proteins Proteomics 1774 (2007) 1173–1183.
[35] T. Ivanovic, M.A. Agosto, K. Chandran, M.L. Nibert, A role for molecular chaperone
Hsc70 in reovirus outer capsid disassembly, J. Biol. Chem. 282 (2007)
12210–12219.
[36] S.L. Nunes, S.K. Calderwood, Heat shock gactor I and the heat shock cognate 70
protein associate in high molecular weight complexes in the cytoplasm of NIH-
3T3 cells, Biochem. Biophys. Res. Commun. 213 (1995) 1–6.
[37] M.U. Alam, J.A. Harken, A.M. Knorn, A.R. Elford, K. Wigmore, P.S. Ohashi, D.G.
Millar, Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune
diabetes in response to beta cell damage, J. Immunol. 183 (2009) 5728–5737.
[38] M. Egerton, R.L. Moritz, R. Druker, A. Kelso, L.J. Simpson, Identification of the 70kD
heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyr-
osine-containing proteins in T lymphocytes, Biochem. Biophys. Res. Commun. 224
(1996) 666–674.
[39] P.S. Wehner, B. Nielsen, M. Hokland, Expression levels of hsc70 and hsp60 are
developmentally regulated during B-cell maturation and not associated to
childhood c-ALL at presentation or relapse, Eur. J. Haematol. 71 (2003) 100–108.
[40] N. Zou, L.H. Ao, J.C. Cleveland, X.P. Yang, X. Su, G.Y. Cai, A. Banerjee, D.A. Fullerton,
X.Z. Meng, Critical role of extracellular heat shock cognate protein 70 in the
myocardial inflammatory response and cardiac dysfunction after global ischemia-
reperfusion, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H2805–H2813.
[41] C.M. Fletcher, T.V. Pestova, C.U.T. Hellen, G. Wagner, Structure and interactions of
the translation initiation factor eIF1, EMBO J. 18 (1999) 2631–2637.
[42] N. Methot, M.S. Song, N. Sonenberg, A region rich in aspartic acid, arginine,
tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B
(eIF4B) self-association and interaction with eIF3, Mol. Cell. Biol. 16 (1996)
5328–5334.
[43] L. Valasek, K.H. Nielsen, A.G. Hinnebusch, Direct eIF2–eIF3 contact in the
multifactor complex is important for translation initiation in vivo, EMBO J. 21
(2002) 5886–5898.
[44] X.H. Chen, S.B. Fu, F. Chen, H.Y. Chen, Z. Chen, Identification of tumor-associated
antigens in human hepatocellular carcinoma by autoantibodies, Oncol. Rep. 20
(2008) 979–985.
[45] W.Y. Shen, H. Liu, Y.N. Yu, Translation initiation proteins, ubiquitin-proteasome
system related proteins, and 14-3-3 proteins as response proteins in FL cells
exposed to anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide, Proteomics
8 (2008) 3450–3468.
[46] H.R. Zhou, A.S. Lau, J.J. Pestka, Role of double-stranded RNA-activated protein
kinase R (PKR) in deoxynivalenol-induced ribotoxic stress response, Toxicol. Sci.
74 (2003) 335–344.
[47] J.I. Azconaolivera, Y. Ouyang, J. Murtha, F.S. Chu, J.J. Pestka, Induction of cytokine
messenger-RNAs in mice after oral -exposure to the trichothecene vomitoxin
(deoxynivalenol) — Relationship to toxin distribution and protein-synthesis
inhibition, Toxicol. Appl. Pharmacol. 133 (1995) 109–120.
[48] Y.J. Chung, H.R. Zhou, J.J. Pestka, Transcriptional and posttranscriptional roles
for p38 mitogen-activated protein kinase in upregulation of TNF-alpha
expression by deoxynivalenol (vomitoxin), Toxicol. Appl. Pharmacol. 193
(2003) 188–201.
[49] A.M. Osman, J.L.A. Pennings, M. Blokland, A. Peijnenburg, H. van Loveren, Protein
expression profiling of mouse thymoma cells upon exposure to the trichothecene
deoxynivalenol (DON): implications for its mechanism of action, J. Immunotox-
icol. 7 (2010) 147–156.
[50] L. Miranda, S. Horman, I. De Potter, L. Hue, J. Jensen, M.H. Rider, Effects of
contraction and insulin on protein synthesis, AMP-activated protein kinase and
phosphorylation state of translation factors in rat skeletal muscle, Pflugers Arch.
Eur. J. Physiol. 455 (2008) 1129–1140.
[51] N.T. Redpath, N.T. Price, K.V. Severinov, C.G. Proud, Regulation of elongation
factor-2 by multisite phosphorylation, Eur. J. Biochem. 213 (1993) 689–699.
[52] A.G. Ryazanov, E.A. Shestakova, P.G. Natapov, Phosphorylation of elongation
factor 2 by EF-2 kinase affects rate of translation, Nature 334 (1988) 170–173.
[53] J.E. Kim, S.R. Tannenbaum, F.M. White, Global phosphoproteome of HT-29 human
colon adenocarcinoma cells, J. Proteome Res. 4 (2005) 1339–1346.
[54] L. Orsatti, E. Forte, L. Tomei, M. Caterino, A. Pessi, F. Talamo, 2-D Difference in gel
electrophoresis combined with Pro-Q Diamond staining: a successful approach
for the identification of kinase/phosphatase targets, Electrophoresis 30 (2009)
2469–2476.
[55] S. Doll, J.A. Schrickx, S. Danicke, J. Fink-Gremmels, Deoxynivalenol-induced
cytotoxicity, cytokines and related genes in unstimulated or lipopolysaccharide
stimulated primary porcine macrophages, Toxicol. Lett. 184 (2009) 97–106.
[56] S.G. Li, A.D. Couvillon, B.B. Brasher, R.A. Van Etten, Tyrosine phosphorylation of
Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory
mechanism for tyrosine kinase signaling, EMBO J. 20 (2001) 6793–6804.
[57] E. Haines, P. Minoo, Z. Feng, N. Resalatpanah, X.M. Nie, M. Campiglio, L. Alvarez, E.
Cocolakis, M. Ridha, M. Di Fulvio, J. Gomez-Cambronero, J.J. Lebrun, S. Ali, Tyrosine
phosphorylation of GRB2: role in prolactin/epidermal growth factor cross talk in
mammary epithelial cell growth and differentiation, Mol. Cell. Biol. 29 (2009)
2505–2520.
[58] N. Engels, L.M. Konig, C. Heemann, J. Lutz, T. Tsubata, S. Griep, V. Schrader, J.
Wienands, Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and IgE
provides antigen receptor-intrinsic costimulation to class-switched B cells, Nat.
Immunol. 10 (2009) 1018–1764.
[59] T. Kaji, S. Hachimura, W. Ise, S. Kaminogawa, Proteome analysis reveals caspase
activation in hyporesponsive CD4 T lymphocytes induced in vivo by the oral
administration of antigen, J. Biol. Chem. 278 (2003) 27836–27843.
[60] Y. Liu, W.G. Zhang, Identification of a new transmembrane adaptor protein that
constitutively binds Grb2 in B cells, J. Leukoc. Biol. 84 (2008) 842–851.
[61] Y. Moon, H. Yang, S.H. Lee, Modulation of early growth response gene I and
interieukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in
human epithelial intestine 407 cells, Biochem. Biophys. Res. Commun. 362 (2007)
256–262.
[62] J.J. Pestka, R.L. Uzarski, Z. Islam, Induction of apoptosis and cytokine production in
the Jurkat human T cells by deoxynivalenol: role of mitogen-activated protein
kinases and comparison to other 8-ketotrichothecenes, Toxicology 206 (2005)
207–219.
[63] H.R. Zhou, Z. Islam, J.J. Pestka, Rapid, sequential activation of mitogen-activated
protein kinases and transcription factors precedes proinflammatory cytokine
mRNA expression in spleens of mice exposed to the trichothecene vomitoxin,
Toxicol. Sci. 72 (2003) 130–142.
857A. Nogueira da Costa et al. / Biochimica et Biophysica Acta 1814 (2011) 850–857
